| abstract |
Compounds of formula (I) are described (see formula) wherein R 1 is hydroxyl, C 1-4 alkoxy, C 3-7 cycloalkoxy, C 3-7 cycloalkylmethoxy, 2,2-difluoroethoxy, or C 1-4 alkoxy completely or predominantly substituted with fluorine , R2 is hydroxy, C1-4 alkoxy, C3-7 cycloalkoxy, C3-7 cycloalkylmethoxy, or C1-4 alkoxy completely or predominantly substituted with fluorine, or wherein R1 and R2 together are a C1 alkylenedioxy group -2, R3 is hydrogen or C1-4 alkyl, R31 is hydrogen or C1-4 alkyl, or, is a first modality (modality a) according to the present invention, R4 is -O-R41, wherein R41 is hydrogen . C1-4 alkyl, C1-4 alkoxy-C1-4 alkyl, hydroxyC2-4 alkyl, C1-7 alkylcarbonyl, or C1-4 alkyl completely or predominantly substituted with fluorine, and R5 is hydrogen or C1-4 alkyl, or, in a second embodiment (mode b) according to the present invention, R4 is hydrogen or C1-4 alkyl, and R5 is -O-R51, wherein R51 is hydrogen, C1-4 alkyl, C1-4 alkoxy-C1 alkyl- 4, C2-4 hydroxyalkyl, C1-7 alkylcarbonyl, or C1-4 alkyl completely or predominantly substituted with fluorine, R6 is hydrogen, halogen, C1-4 alkyl or C1-4 alkoxy, or predominantly substituted with fluorine, R + 6 is halogen hydrogen, C1-4alkyl or C1-4alkoxy, or in a first aspect (aspect 1) according to the present invention, R7 is N (R8) R9, or, in a second aspect (aspect 2) according to The present invention, R7 is -NH-N (R18) R19, as effective new inhibitors of PDE4. |